{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T21:36:07Z","timestamp":1773696967925,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ad.2019.07.005","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T22:44:46Z","timestamp":1576709086000},"page":"115-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Estudio Delphi para el uso de apremilast en la psoriasis"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-0771","authenticated-orcid":false,"given":"J.M.","family":"Carrascosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6007-7320","authenticated-orcid":false,"given":"I.","family":"Belinch\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bustinduy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Herranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2019.07.005_bib0170","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet."},{"key":"10.1016\/j.ad.2019.07.005_bib0175","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (pde4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase iii, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2019.07.005_bib0180","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: A phase iii, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2019.07.005_bib0185","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.ad.2010.09.001","article-title":"Tratamiento de la psoriasis del cuero cabelludo. Revisi\u00f3n de la evidencia y Consenso Delphi del Grupo de Psoriasis de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda","volume":"101","author":"Puig","year":"2010","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2019.07.005_bib0190","unstructured":"Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, L\u00e1zaro P, et al. The RAND\/UCLA appropriateness method user's manual. Library of Congress Cataloging-in-Publication Data. Santa Monica, CA: RAND; 2001."},{"key":"10.1016\/j.ad.2019.07.005_bib0195","first-page":"1","article-title":"The Delphi technique: Making sense of consensus","volume":"12","author":"Hsu","year":"2007","journal-title":"Pract Assess Res Eval"},{"key":"10.1016\/j.ad.2019.07.005_bib0200","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/09537320120088174","article-title":"Strategic planning for high-tech product development","volume":"13","author":"Scott","year":"2001","journal-title":"Technol Anal Strateg Manag."},{"key":"10.1016\/j.ad.2019.07.005_bib0205","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions","volume":"65","author":"Menter","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2019.07.005_bib0210","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/09546634.2018.1443200","article-title":"Defining and treating moderate plaque psoriasis: A dermatologist survey","volume":"29","author":"Knuckles","year":"2018","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.ad.2019.07.005_bib0215","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.ad.2017.07.002","article-title":"Moderate psoriasis: A proposed definition","volume":"108","author":"Llamas-Velasco","year":"2017","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2019.07.005_bib0220","unstructured":"Reich K, Bomas S, Korge B, Schwichtenberg U, Mentz H, Groegel K, et al. Physician- and patient-reported outcomes with apremilast for patients with plaque psoriasis during routine clinical care in germany: A second interim analysis. Proceedings of the AAD Annual Meeting. San Diego, CA, 16-20 de febrero de 2018."},{"key":"10.1016\/j.ad.2019.07.005_bib0225","unstructured":"Iversen L, Paul C, Cirulli J, Chen R, Andersson C, Yamauchi P. Efficacy of apremilast versus placebo in patients with lower plaque psoriasis disease activity: Results of a pooled post hoc analysis of the ESTEEM 1 and 2 trials. Proceedings of the 26th Congress of the EADV. Geneva, Switzerland, 13-17 de septiembre de 2017."},{"key":"10.1016\/j.ad.2019.07.005_bib0230","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/jdv.14832","article-title":"Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis","volume":"32","author":"Papadavid","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2019.07.005_bib0235","unstructured":"Arag\u00f3n-Miguel R, Calleja-Algarra A, Pinilla-Mart\u00edn B, Andr\u00e9s-Lencina JJ, Vico-Alonso C, S\u00e1nchez-Vel\u00e1zquez A, et al. Apremilast in plaque psoriasis: A retrospective, real-life study up to 12-month observation. Proceedings of the 2019 AAD Annual Meeting. Washington, D. C., 1-5 de marzo de 2019."},{"key":"10.1016\/j.ad.2019.07.005_bib0240","unstructured":"Lukoviek V, Arteaga-Henr\u00edquez M, Ram\u00edrez-Conchas J, Markthaler M, Pestana-Eliche M, Garc\u00eda-Bustinduy M, et al. Real-world experience with apremilast for the treatment of psoriasis: Retrospective single-centre study in the Canary Islands. Proceedings of the 2019 AAD Annual Meeting. Washington, D. C., 1-5 de marzo de 2019."},{"key":"10.1016\/j.ad.2019.07.005_bib0245","unstructured":"De Jong E, van den Reek J, van Vugt L, de Groot M, Koopmans K, Verkouteren B, et al. Characteristics of psoriasis patients who continue apremilast treatment in real life in the Netherlands\u2014Results from the prospective, multicenter, real-world APRIL study. Proceedings of the 2019 AAD Annual Meeting. Washington, D. C., 1-5 de marzo de 2019."},{"key":"10.1016\/j.ad.2019.07.005_bib0250","unstructured":"CatSalut. Servei Catal\u00e0 de la Salut. Apremilast (Psoriasi). Tractament de la psoriasi en plaques cr\u00f2nica de moderada a greu en pacients adults que no responen, tenen contraindicada o no toleren un altre tractament sist\u00e8mic, incl\u00f2s ciclosporina, metotrexat o psoral\u00e8n i llum ultravioleta A (PUVA). Informe t\u00e8cnic del Consell Assessor de la Medicaci\u00f3 Hospital\u00e0ria de Dispensaci\u00f3 Ambulat\u00f2ria (CAMHDA). 2016. [consultado 3 Sep 2018]. Disponible en: https:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/proveidors_professionals\/medicaments_farmacia\/harmonitzacio\/informes\/apremilast-psoriasi\/informe-CAMHDA-apremilast.pdf"},{"key":"10.1016\/j.ad.2019.07.005_bib0255","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1080\/09546634.2018.1467536","article-title":"Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: Systematic review of the literature and meta-analysis","volume":"29","author":"Carrascosa","year":"2018","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.ad.2019.07.005_bib0260","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/jdv.14647","article-title":"Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: Results from a double-blind, placebo-controlled, randomized study","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2019.07.005_bib0265","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2016.02.1164","volume":"75","author":"Bissonnette","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2019.07.005_bib0270","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase iii randomized, controlled trials (ESTEEM 1 and ESTEEM 2)","volume":"74","author":"Rich","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2019.07.005_bib0275","unstructured":"Reich K, Bomas S, Korge B, Manasterski M, Schwichtenberg U, Altmann M, et al. First \u201creal-world\u201d insights on apremilast therapy for patients with plaque psoriasis from the LAPIS-PSO study: An interim analysis. Proceedings of the 75th Annual Meeting of the American Academy of Dermatology. Orlando, FL, 3-7 de marzo de 2015."},{"key":"10.1016\/j.ad.2019.07.005_bib0280","doi-asserted-by":"crossref","unstructured":"Van Voorhees A, Stein Gold L, Lebwohl M, Strober B, Lynde C, Tyring S, et al. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3, multicenter, randomized, placebo-controlled, double-blind study. Proceedings of the Winter Clinical Dermatology Conference - Hawaii. Koloa, HI, 18-23 de enero de 2019.","DOI":"10.1016\/j.jaad.2020.01.072"},{"key":"10.1016\/j.ad.2019.07.005_bib0285","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A phase iii, randomized, controlled trial of apremilast in patients with psoriatic arthritis: Results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J Rheumatol."},{"key":"10.1016\/j.ad.2019.07.005_bib0290","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: A phase iii, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ad.2019.07.005_bib0295","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ad.2019.07.005_bib0300","unstructured":"CHMP. Anexo I - Ficha t\u00e9cnica o resumen de las caracter\u00edsticas del producto. Otezla [consultado 11 Ene 2019]. Disponible en: https:\/\/www.ema.europa.eu\/documents\/product-information\/otezla-epar-product-information_es.pdf"},{"key":"10.1016\/j.ad.2019.07.005_bib0305","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","article-title":"Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for\u2265156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)","volume":"77","author":"Crowley","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2019.07.005_bib0310","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/jdv.14454","article-title":"European S3-guideline on the systemic treatment of psoriasis vulgaris - Update apremilast and secukinumab - EDF in cooperation with EADV and IPC","volume":"31","author":"Nast","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2019.07.005_bib0315","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/bjd.14032","article-title":"Risk of depression in women with psoriasis: A cohort study","volume":"173","author":"Dommasch","year":"2015","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2019.07.005_bib0320","first-page":"891","article-title":"The risk of depression, anxiety, and suicidality in patients with psoriasis: A population-based cohort study","volume":"146","author":"Kurd","year":"2010","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.ad.2019.07.005_bib0325","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/1203475417748886","article-title":"Management of common side effects of apremilast","volume":"22","author":"Langley","year":"2018","journal-title":"J Cutan Med Surg."},{"key":"10.1016\/j.ad.2019.07.005_bib0330","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1111\/jdv.15061","article-title":"Adverse events associated with apremilast use and withdrawal for psoriasis in a real-world setting","volume":"32","author":"Lee","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731019303746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731019303746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:09:52Z","timestamp":1757552992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731019303746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0001731019303746"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2019.07.005","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estudio Delphi para el uso de apremilast en la psoriasis","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2019.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of AEDV.","name":"copyright","label":"Copyright"}]}}